Vertex Pharmaceuticals Incorporated

Published : August 19th, 2015

Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts

( 0 vote, 0/5 ) Print article
  Article Comments Comment this article Rating Follow Company  
0
Send
0
comment
Keywords :   Australia | Canada | China | Europe | Lead |

Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts

BOSTON--(BUSINESS WIRE)--

Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year scholarship to pursue their education in Science, Technology, Engineering and Math (STEM) at any UMass campus. The annual scholarship is part of a broad program developed by Vertex to enhance STEM education for Boston’s youth.

This year’s recipients are two students from Excel High School.

  • Cankang Wu plans to study engineering at UMass Amherst. Cankang emigrated with his family from China and will be the first to attend college. As a child he developed an early interest in engineering and technology after spending his days at his father’s wood-processing factory.
  • Gladynel Baez will attend UMass Boston to study biology and has aspirations of becoming a doctor. She was inspired to pursue a career in science after losing two aunts and her grandfather to cancer and spending time in Vertex’s Learning Lab.

In 2012 Vertex solidified its commitment to STEM education and Boston’s youth through a comprehensive program that includes:

  • Annual four-year Vertex Science Leaders Scholarship to a UMass campus;
  • Thomas M. Menino Learning Lab - a 3,000 square foot classroom and laboratory space in our Fan Pier campus dedicated to enhancing science education among Boston Public School students;
  • High school and college internships;
  • Science Fair Mentorship program - students are paired with a Vertex mentor and receive guidance on science fair projects at the school and state level.

“Vertex is committed to developing the next generation of scientific leaders by sparking and fostering an early interest in science,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. “Our programs fill an important need for hands-on training and will help reduce achievement and access gaps for underserved students, while preparing them for a bright future in life sciences. For the past two years Cankang and Gladynel grew with Vertex as interns and spent extensive time in our Learning Lab. We’re delighted to see the tremendous passion they’ve developed for STEM.”

“In order for our young people to have bright futures, we must do our part to create the opportunities that foster pathways to success,” said Mayor Martin J. Walsh. “I thank Vertex for continuing to support our future and our community, and congratulate Cankang and Gladynel on these deserving honors.”

“We are honored to welcome Cankang and Gladynel to the UMass family,” said University of Massachusetts President Martin T. Meehan. “We share Vertex’s commitment to investing in Boston’s youth and enhancing science education in the community.”

This year Vertex also is partnering with Bottom Line, an organization that helps underserved, first-generation students get into college and succeed through mentoring and support throughout their college careers. Today, August 19, 2015 Vertex will host Bottom Line’s Annual Success Send-Off Event to celebrate the start of school for more than 200 first-generation college students who are part of the Bottom Line program. Students like Cankang and Gladynel will participate in team building activities and have the opportunity to meet their Bottom Line Success Counselor and other Bottom Line students attending the same college in the fall.

“We’re proud of these students and all the hard work they’ve put into their academics to get them here,” said Mike Wasserman, Massachusetts Executive Director at Bottom Line. “It’s partnerships like this, with Vertex and UMass, that allow us to provide guidance and support for students who want to thrive and grow, particularly in this next chapter of their lives and we can’t wait to see the great things they accomplish.”

About Vertex
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit www.vrtx.com.

About the University of Massachusetts
The University of Massachusetts has been serving the Commonwealth of Massachusetts with dedication and distinction for the past 150 years and is consistently rated as one of the world's best universities. Each year UMass educates more than 70,000 students and confers more than 15,000 degrees at its five campuses located in Amherst, Boston, Dartmouth, Lowell and Worcester.

About Bottom Line
Bottom Line was founded in Boston in 1997 to help low-income and first-generation students get into college, graduate from college and go far in life. The organization serves approximately 3,000 high school seniors and college students from Boston and Worcester.

(VRTX-GEN)

Read the rest of the article at finance.yahoo.com
Data and Statistics for these countries : Australia | Canada | China | All
Gold and Silver Prices for these countries : Australia | Canada | China | All

CODE :
Follow and Invest
Add to watch list Add to your portfolio Add or edit a note
Add Alert Add to Watchlists Add to Portfolio Add Note
ProfileMarket
Indicators
VALUE :
Projects & res.
Press
releases
Annual
report
RISK :
Asset profile
Contact Cpy

Vertex Pharma is based in United states of america.

Vertex Pharma is listed in United States of America. Its market capitalisation is US$ 114.7 billions as of today (€ 108.5 billions).

Its stock quote reached its lowest recent point on March 12, 2004 at US$ 10.00, and its highest recent level on November 15, 2024 at US$ 460.61.

Vertex Pharma has 249 070 000 shares outstanding.

Your feedback is appreciated, please leave a comment or rate this article.
Rate : Average note :0 (0 vote) View Top rated
 
Corporate news of
1/27/2016Will Vertex Pharmaceuticals’ Valuation Multiple Improve?
1/26/2016Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - t...
1/26/20165:23 pm Vertex Pharma: Health Canada approves PrORKAMBI
1/26/2016Orkambi: Recent Addition to the Vertex Portfolio
1/26/2016Vertex draws upside bet before earnings
1/25/2016Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?
1/25/2016What Are Wall Street’s Estimates for Vertex Pharmaceuticals?
1/25/2016Vertex Pharmaceuticals: What Are Analysts’ Estimates?
1/20/2016Despite Market and Sector Risks, Why Credit Suisse Now Loves...
1/18/2016Nivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis
1/15/20164 Biotech Stocks Looking Good this Earnings Season
1/15/2016Vertex Pharmaceuticals (VRTX) Jumps: Stock Moves Up 5.8%
1/5/2016Vertex Announces Upcoming Presentation at the J.P. Morgan He...
12/30/2015Vertex Up 3.2% as Healthcare Sector Continued to Lure Invest...
12/23/2015Vertex Drives IBB’s Large-Caps after Losing for Two Days
12/1/2015Do Hedge Funds Love Intercontinental Exchange Inc (ICE)?
11/27/2015The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, ...
11/23/2015Vertex to Present at the Piper Jaffray Healthcare Conference...
11/23/2015Vertex Appoints Michael J. Parini as Executive Vice Presiden...
11/20/2015Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaft...
11/19/2015Vertex Rises on Two EU Approvals for Drug, Leads XLV’s Large...
11/4/2015Vertex to Present at the Credit Suisse Healthcare Conference...
11/2/2015Health-Care Subpoenas: Should We Start to Worry?
11/2/2015Here’s Why These Four Stocks Are Trending Today
11/2/2015IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Inves...
10/31/2015Vertex Pharma receives subpoena from Department of Justice
10/30/2015Law Offices of Howard G. Smith Commences Investigation on Be...
10/30/2015Vertex, Mylan, CVS subpoenaed by federal agencies
10/30/2015SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On...
10/30/2015Nivalis (NVLS): A Surprise in Store this Earnings Season?
10/29/2015Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View
10/29/2015Edited Transcript of VRTX earnings conference call or presen...
10/28/2015Vertex Reports Third Quarter 2015 Financial Results
10/28/2015Vertex reports 3Q loss
10/28/20154:07 pm Vertex Pharma beats by $0.14, beats on revs; raises ...
10/27/2015Will Orkambi Help Vertex (VRTX) Post a Lower Loss in Q3?
10/26/2015Vertex and CRISPR Therapeutics Establish Collaboration to Us...
10/26/20158:03 am Vertex Pharma and CRISPR Therapeutics enter strategi...
10/20/2015Oppenheimer Incrementally More Bullish on Gilead, Remains Ca...
10/12/2015Why Energy Stocks Outperformed the Broad Market on October 6
10/9/2015Vertex to Announce Third Quarter 2015 Financial Results on O...
10/8/2015SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Invest...
10/8/2015Vertex's Kalydeco Gets Priority Review for Expanded Use
10/8/2015Vertex Announces Significant Progress in Its Development Eff...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015BioMarin Pharmaceutical Takes a Nosedive Last Week
10/1/2015The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead...
9/29/2015Regeneron and Mylan End Up in Green for the Week
9/28/2015Why Argus Thinks Now Is the Time to Buy Vertex
9/25/2015IBB Remained Flat Last Week
9/25/2015Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaf...
9/23/2015XBI’s Biotechnology Stocks Rose Week of September 11
9/22/20155 Biotech Stocks Hit Hard by Hillary Clinton's Tweet
9/22/2015Vertex Outperforms XLV on a Year-to-Date Basis
9/21/2015Biotech stocks fall on Clinton vow to fight 'price gouging'
9/18/2015SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Invest...
9/16/2015XLV and XBI Outperform Benchmark Indexes from August 25–31
9/14/2015Amgen And Biogen Lead Short Interest Surge In Biotechs
9/14/2015Vertex Helps Biotechnology Sector Outperform
9/14/2015How Will Vertex Solve Its Falling Revenue Woes?
9/14/2015Vertex Pharma's Orkambi Gives It Huge Potential, Says Barcla...
9/11/2015Vertex and Biogen Outperformd XLV and SPY
9/8/2015Vertex to Present at the Morgan Stanley Healthcare Conferenc...
8/22/2015How Does Vertex Compare to Its Peers?
8/21/2015Vertex Stock Rises after 2Q15 Results Announcement
8/21/2015Will Orkambi Be a Game Changer for Vertex?
8/19/2015Vertex Awards Two Boston Public High School Students the Ver...
8/11/2015What Drove Vertex’s Revenue in 2Q15?
8/11/2015Vertex Reports 2Q15 Revenues of $166.1 Million
8/11/2015What Led Large-Cap Stocks to Outperform Mid and Small Caps?
8/10/2015Key for Investors: How Are Biotech Stocks Trending?
8/10/2015Biotech Stocks Rise Due to a Stable Market: July 31 Week
8/6/2015The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron,...
8/4/20153 Potential Huge Takeover Targets in Biotech
7/31/2015Advanced Estimate: US 2Q Gross Domestic Product Expanded by ...
7/30/2015Vertex Posts Wider Y/Y Loss but Raises Kalydeco Outlook - An...
7/30/2015Large-Cap Healthcare Stocks Outperform Small Caps
7/30/2015Edited Transcript of VRTX earnings conference call or presen...
7/29/2015Vertex Reports Second Quarter 2015 Financial Results
7/29/2015Vertex reports 2Q loss
7/28/2015Will Vertex (VRTX) Surprise with a Lower Loss in Q2? - Analy...
7/28/2015CRBP: Warrant Exercise To Provide Sufficient Cash Through 20...
7/24/2015What to Watch in the Week Ahead and on Monday, July 27
7/21/2015How High? The Backlash Over Rising Prescription Drug Prices ...
7/14/2015Vertex to Announce Second Quarter 2015 Financial Results on ...
7/6/2015Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside
7/5/2015Evercore ISI Analyst Gives Highlights From Vertex's Orkambi ...
7/5/20151:46 pm Vertex Pharma confirms FDA approval of its ORKAMBI t...
7/2/2015Business Highlights
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015FDA clears drug for leading form of cystic fibrosis
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015Vertex Pharma's lung disorder therapy wins FDA nod
7/2/2015Vertex Shares Leap On FDA Approval For Cystic Fibrosis Combo...
7/2/2015FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Med...
6/18/2015Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Direc...
6/12/2015Edited Transcript of VRTX presentation 11-Jun-15 4:20pm GMT
5/8/2015FDA questions benefit of cystic fibrosis drug from Vertex
4/23/2015Why Vertex Pharmaceuticals (VRTX) Stock Might be a Great Pic...
4/21/2015Gilead's Stock Spikes on Possibility of Vertex Deal
4/21/2015Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC C...
4/21/2015Bernstein: It's Time For Gilead To Pull The Trigger On This ...
4/17/2015Biotech Investors Shouldn't Miss These Stocks This Earnings ...
4/15/2015Will a New Vertex Drug for Cystic Fibrosis Become a Budget B...
4/9/2015Vertex to Announce First Quarter 2015 Financial Results on A...
4/8/2015Stock Market News for April 08, 2015 - Market News
3/26/2015The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex,...
3/26/2015One analyst is convinced the biotech stock plunge is 'misgui...
3/24/2015Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - A...
3/24/2015Vertex Treatment May Have High Risk of Failure, Analyst Sugg...
3/24/2015Stock Market News for March 24, 2015 - Market News
3/23/2015Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Re...
3/23/2015Vertex Falls Below Buy Point On Cystic-Fibrosis Drug Data
3/23/2015Pfizer and ImmunoGen are big market movers
3/23/2015ICYMI: Pharmaceutical Stocks Are Moving Big On Monday
Comments closed
 
Latest comment posted for this article
Be the first to comment
Add your comment
NASDAQ (VRTX)
460.61-4.82%
US$ 460.61
11/15 14:03 -23.35
-4.82%
Prev close Open
483.96 478.93
Low High
458.10 479.94
Year l/h YTD var.
392.81 -  516.74 12.10%
52 week l/h 52 week var.
343.00 -  516.74 31.85%
Volume 1 month var.
1,400,148 -4.89%
Produces
Develops
Explores for
 
 
 
Analyse
Interactive chart Add to compare
Interactive
chart
Print Compare Export
You must be logged in to use the porfolio and watchlists (free)
Top Newsreleases
MOST READ
Annual variation
DateVariationHighLow
202413.20%518.35391.02
202340.90%413.00282.41
202230.17%324.75219.10
2021-6.14%238.26176.36
20206.96%306.08197.47
 
5 years chart
 
3 months chart
 
3 months volume chart
 
 
Mining Company News
Plymouth Minerals LTDPLH.AX
Plymouth Minerals Intersects Further High Grade Potash in Drilling at Banio Potash Project - Plannin
AU$ 0.12-8.00%Trend Power :
Santos(Ngas-Oil)STO.AX
announces expected non-cash impairment
AU$ 6.72+0.45%Trend Power :
OceanaGold(Au)OGC.AX
RELEASES NEW TECHNICAL REPORT FOR THE HAILE GOLD MINE
AU$ 2.20+0.00%Trend Power :
Western Areas NL(Au-Ni-Pl)WSA.AX
Advance Notice - Full Year Results Conference Call
AU$ 3.86+0.00%Trend Power :
Stornoway Diamond(Gems-Au-Ur)SWY.TO
Second Quarter Results
 0.02+100.00%Trend Power :
McEwen Mining(Cu-Le-Zn)MUX
TO ACQUIRE BLACK FOX FROM PRIMERO=C2=A0
US$ 8.45+0.48%Trend Power :
Rentech(Coal-Ngas)RTK
Rentech Announces Results for Second Quarter 2017
US$ 0.20-12.28%Trend Power :
KEFIKEFI.L
Reduced Funding Requirement
GBX 0.59-2.80%Trend Power :
Lupaka Gold Corp.LPK.V
Lupaka Gold Receives First Tranche Under Amended Invicta Financing Agreement
CA$ 0.06-8.33%Trend Power :
Imperial(Ag-Au-Cu)III.TO
Closes Bridge Loan Financing
 2.07-1.43%Trend Power :
Guyana Goldfields(Cu-Zn-Pa)GUY.TO
Reports Second Quarter 2017 Results and Maintains Production Guidance
 1.84+0.00%Trend Power :
Lundin Mining(Ag-Au-Cu)LUN.TO
d Share Capital and Voting Rights for Lundin Mining
 13.53+0.67%Trend Power :
Canarc Res.(Au)CCM.TO
Canarc Reports High Grade Gold in Surface Rock Samples at Fondaway Canyon, Nevada
 0.30+0.00%Trend Power :
Havilah(Cu-Le-Zn)HAV.AX
Q A April 2017 Quarterly Report
 0.20+0.00%Trend Power :
Uranium Res.(Ur)URRE
Commences Lithium Exploration Drilling at the Columbus Basin Project
US$ 6.80-2.86%Trend Power :
Platinum Group Metals(Au-Cu-Gems)PTM.TO
Platinum Group Metals Ltd. Operational and Strategic Process ...
 2.26+0.44%Trend Power :
Devon Energy(Ngas-Oil)DVN
Announces $340 Million of Non-Core Asset Sales
US$ 38.50-2.23%Trend Power :
Precision Drilling(Oil)PD-UN.TO
Announces 2017Second Quarter Financial Results
CA$ 8.66-0.35%Trend Power :
Terramin(Ag-Au-Cu)TZN.AX
2nd Quarter Report
AU$ 0.10-4.76%Trend Power :
Sun Res.(Oil)SUR.AX
Released ASX Announcement: Quarterly Activities Report
AU$ 0.00+0.00%Trend Power :
Take advantage of rising gold stocks
  • Subscribe to our weekly mining market briefing.
  • Receive our research reports on junior mining companies
    with the strongest potential
  • Free service, your email is safe
  • Limited offer, register now !
Go to website.